Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in psychotropic formulations.

Samuel Keith1

  • 1Department of Psychiatry and Psychology, University of New Mexico, 2400 Tucker, NE Room 404, Albuquerque, 87131, USA. SKeith@salud.unm.edu

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|May 9, 2006
PubMed
Summary

New psychotropic formulations improve treatment convenience, reduce side effects, and enhance patient compliance for psychiatric illnesses. These advanced drug delivery systems offer better outcomes in managing conditions like depression and schizophrenia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.

Expert review of neurotherapeutics·2008
Same author

Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2003
See all related articles

Area of Science:

  • Pharmacology
  • Psychiatry
  • Drug Delivery Systems

Background:

  • Pharmacotherapy success depends on efficacy, dosage forms, compliance, and side effect reduction.
  • Innovative drug delivery systems aim to optimize therapy outcomes by improving drug delivery and patient adherence.
  • Addressing suboptimal therapy outcomes is crucial for effective psychiatric treatment.

Purpose of the Study:

  • To review advancements in formulations for psychotropic agents used in treating psychiatric disorders.
  • Focus on new formulations for depression, attention deficit hyperactivity disorder, and psychotic disorders.

Main Methods:

  • Literature search of MEDLINE and EMBASE databases (2002-2005).
  • Keywords included 'psychotropic', 'antipsychotic', 'antidepressant', 'anxiolytic' combined with terms for new formulations and delivery technologies.

Related Experiment Videos

  • Included searches for controlled-release, extended-release, fast-acting, and injectable formulations.

    • Main Results:

    • New antidepressant formulations include extended-release, orally disintegrating, and transdermal systems.
    • Long-acting stimulants for ADHD reduce dosing frequency.
    • Novel atypical antipsychotic formulations offer rapid-acting injections, liquids, and fast-dissolving tablets for acute and specific patient populations.
    • Sustained-release formulations, including long-acting antipsychotics, improve compliance and long-term management.

    Conclusions:

    • Advanced psychotropic formulations provide benefits over older ones, including convenience, improved side effect profiles, efficacy, and faster onset of action.
    • Enhanced treatment satisfaction and compliance through new formulations can lead to better patient prognosis and outcomes.
    • These innovations are valuable for both acute and outpatient psychiatric care.